Boston Scientific announces results for fourth quarter and full year 2025

MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period.

PRNewsWire • Feb 4, 2026

GMED vs. PEN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Feb 3, 2026

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights

GlobeNewsWire • Jan 27, 2026

Artisan Small Cap Fund Q4 2025 Portfolio Activity

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

Seeking Alpha • Jan 23, 2026

Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last?

Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research • Jan 16, 2026

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire • Jan 16, 2026

Boston Scientific to buy Penumbra in deal valued at $14.5 billion

Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.

Reuters • Jan 15, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN)

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Penumbra, Inc. (NYSE: PEN) related to its sale to Boston Scientific Corporation.

PRNewsWire • Jan 15, 2026

Shareholder Alert: The Ademi Firm investigates whether Penumbra, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Jan. 15, 2026 /PRNewswire/ -- Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Boston Scientific. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Jan 15, 2026

PEN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Penumbra, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock is fair to Penumbra shareholders. Halper Sadeh encourages Penumbra shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Business Wire • Jan 15, 2026